Compare CVS Health Corp (CVS) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Schwab US Dividend Equity ETF — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.29B), while Schwab US Dividend Equity ETF trades at $33.06 (market cap $110.56B). The key difference: CVS Health Corp and Schwab US Dividend Equity ETF are close in size by market cap, and CVS Health Corp pays a 3.03% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| CVS | SCHD | |
|---|---|---|
Market Cap | $112.29B | $110.56B |
Volume | 7,763,676 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $35.21 |
52-Week Low | $70.08 | $26.44 |
Typical Hold Time | 83 Days | 62 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
SCHD trades at $33.09, up 1.35% with a bullish technical signal despite mixed moving averages. Recent news highlights its outperformance versus the S&P 500 in 2026 and dividend growth, though the ETF faces pressure from rising interest rates. Support sits at $32-$33, with resistance at $33-$34. The RSI readings are neutral, while ADX signals conflicting trend strength.
Outlook: SCHD offers income growth and lower fees, appealing for dividend investors, but interest rate sensitivity and defensive tilts pose risks. The ETF's rule-based approach may miss high-growth stocks, as seen with Broadcom. Near-term performance hinges on macroeconomic trends and dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
